IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.663
NA - Nord America 15.696
EU - Europa 8.703
SA - Sud America 3.053
AF - Africa 906
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 9
Totale 45.061
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.148
SG - Singapore 6.962
VN - Vietnam 2.533
IT - Italia 2.496
CN - Cina 2.339
BR - Brasile 2.271
IE - Irlanda 1.575
BD - Bangladesh 1.563
HK - Hong Kong 1.408
SE - Svezia 1.258
FR - Francia 663
NL - Olanda 641
ZA - Sudafrica 577
DE - Germania 565
IN - India 362
GB - Regno Unito 283
AR - Argentina 279
CA - Canada 253
FI - Finlandia 228
RU - Federazione Russa 214
AT - Austria 209
IQ - Iraq 158
TR - Turchia 152
MX - Messico 151
JP - Giappone 135
EC - Ecuador 133
IR - Iran 126
ID - Indonesia 120
KR - Corea 107
CO - Colombia 98
PK - Pakistan 97
PH - Filippine 86
UZ - Uzbekistan 80
ES - Italia 79
VE - Venezuela 79
UA - Ucraina 73
BE - Belgio 70
PL - Polonia 70
MA - Marocco 65
PY - Paraguay 61
MY - Malesia 60
CI - Costa d'Avorio 54
TH - Thailandia 53
SA - Arabia Saudita 52
CL - Cile 50
EG - Egitto 46
TN - Tunisia 45
TW - Taiwan 40
CZ - Repubblica Ceca 39
UY - Uruguay 28
JO - Giordania 27
KE - Kenya 27
LT - Lituania 27
AU - Australia 26
PE - Perù 26
AE - Emirati Arabi Uniti 24
AL - Albania 24
AZ - Azerbaigian 23
BO - Bolivia 23
DK - Danimarca 21
DO - Repubblica Dominicana 21
NP - Nepal 20
IL - Israele 19
KZ - Kazakistan 19
RO - Romania 18
HN - Honduras 17
CR - Costa Rica 16
ET - Etiopia 16
PS - Palestinian Territory 16
CH - Svizzera 15
PA - Panama 15
DZ - Algeria 14
SV - El Salvador 14
BG - Bulgaria 13
JM - Giamaica 13
OM - Oman 13
EE - Estonia 12
GT - Guatemala 12
LB - Libano 12
PT - Portogallo 12
RS - Serbia 12
BH - Bahrain 11
HU - Ungheria 11
GR - Grecia 10
LU - Lussemburgo 10
NG - Nigeria 10
QA - Qatar 10
SN - Senegal 10
AO - Angola 9
BY - Bielorussia 9
HR - Croazia 9
NI - Nicaragua 9
TT - Trinidad e Tobago 9
KW - Kuwait 8
MD - Moldavia 7
KG - Kirghizistan 6
PR - Porto Rico 6
BB - Barbados 5
LV - Lettonia 5
LY - Libia 5
Totale 44.960
Salva come PNG Salva come JPEG
Città #
Singapore 3.301
Ashburn 2.052
Chandler 1.909
San Jose 1.818
Dublin 1.558
Hong Kong 1.347
Dallas 1.233
Santa Clara 1.066
Ho Chi Minh City 818
Boardman 722
Hanoi 598
Beijing 578
Johannesburg 513
New York 495
Lauterbourg 447
Los Angeles 387
Princeton 298
Milan 293
Shanghai 225
São Paulo 215
Rome 203
Munich 200
Council Bluffs 188
Buffalo 168
Parma 161
Vienna 161
Bologna 147
Helsinki 128
Ann Arbor 122
Hefei 116
Nuremberg 107
Haiphong 103
Des Moines 102
Da Nang 100
Frankfurt am Main 94
Moscow 93
Tehran 92
Columbus 90
Chicago 87
Tokyo 84
Atlanta 80
Rio de Janeiro 80
Turku 78
London 72
Orem 70
Wilmington 69
Tashkent 67
Montreal 66
Naples 66
Toronto 62
Denver 60
Seattle 59
Brooklyn 57
Baghdad 55
Marseille 55
Abidjan 54
San Francisco 54
Curitiba 53
Warsaw 53
Brussels 51
Chennai 51
Phoenix 51
Bremen 50
Jakarta 50
Boston 47
Quito 47
Biên Hòa 46
Modena 45
Dhaka 44
Florence 44
Belo Horizonte 43
Verona 43
Mexico City 42
Amsterdam 41
Genoa 41
The Dalles 41
Brasília 39
Guayaquil 38
Guangzhou 37
Hải Dương 37
Pune 37
Houston 36
Stockholm 36
Seoul 35
Tianjin 35
Poplar 33
Istanbul 32
Lahore 31
Turin 31
Can Tho 30
Jacksonville 30
Dearborn 29
Mumbai 29
New Delhi 29
Asunción 28
Charlotte 28
Kuala Lumpur 28
Reggio Emilia 28
Nanjing 27
Amman 26
Totale 25.175
Salva come PNG Salva come JPEG
Nome #
Adjusted Skeletal Muscle Index (aSMI) correlates with outcome in metastatic Renal Cancer Cell (mRCC) patients (pts) treated with first line (1L) immunotherapy (IT) 650
LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial 280
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 238
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 218
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 204
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 202
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 195
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 190
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 188
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 184
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 182
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 180
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK 180
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 179
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?—a narrative review 178
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 176
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 176
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 175
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 174
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 172
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma 170
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 167
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 167
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 167
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 166
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 162
Review on radiological evolution of COVID-19 pneumonia using computed tomography 158
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 157
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 157
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 155
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 155
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 154
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 154
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 153
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 152
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 151
1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15) 151
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 151
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 150
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 148
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 148
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset 148
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 147
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 147
Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study 146
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 146
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) 145
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 145
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 144
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 144
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 144
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 142
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 142
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study 141
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report 141
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 140
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 139
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 139
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 138
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 137
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 137
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. 137
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 136
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 135
The Role of CT Imaging in Characterization of Small Renal Masses 132
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 132
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project 130
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 130
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review 130
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 130
Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta–lesion attenuation difference (ALAD) on contrast-enhanced CT 130
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 128
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 128
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial 128
P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden 126
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 125
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma 124
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 123
112 Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors 122
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 119
1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) 119
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 119
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 119
A wide skull osteolytic metastasis in advanced breast cancer 119
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study) 119
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 118
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis 117
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 117
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) 117
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 116
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 116
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer 116
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 116
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 115
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 115
Outcomes of post-progression therapies in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) progressing after docetaxel (DOC): Real-world data from an Italian multicenter observational study (ECHOS trial) 115
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program 114
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 114
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 114
Totale 15.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 0 0 12
2021/20221.466 9 10 13 30 5 117 319 100 61 25 100 677
2022/20236.059 710 740 558 380 457 586 80 316 1.925 27 203 77
2023/20242.659 135 225 103 109 290 542 204 125 178 154 189 405
2024/202510.042 157 697 754 408 903 1.145 418 456 1.254 1.204 727 1.919
2025/202624.901 1.633 1.890 3.179 2.016 2.965 1.081 2.523 854 2.758 1.866 2.711 1.425
Totale 45.712